6.73
0.44 (7.00%)
| Previous Close | 6.29 |
| Open | 6.33 |
| Volume | 8,737,740 |
| Avg. Volume (3M) | 6,570,375 |
| Market Cap | 1,090,058,112 |
| Price / Earnings (TTM) | 2.45 |
| Price / Sales | 0.840 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Profit Margin | 38.14% |
| Operating Margin (TTM) | 77.40% |
| Diluted EPS (TTM) | 2.75 |
| Quarterly Revenue Growth (YOY) | 610.30% |
| Quarterly Earnings Growth (YOY) | 179.90% |
| Current Ratio (MRQ) | 2.06 |
| Operating Cash Flow (TTM) | -189.21 M |
| Levered Free Cash Flow (TTM) | 61.88 M |
| Return on Assets (TTM) | 19.97% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Novavax, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -4.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -2.25 |
|
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 8.78% |
| % Held by Institutions | 57.29% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 7.00 (JP Morgan, 4.01%) | Sell |
| Median | 6.50 (-3.42%) | |
| Low | 6.00 (Citigroup, -10.85%) | Sell |
| Average | 6.50 (-3.42%) | |
| Total | 2 Sell | |
| Avg. Price @ Call | 6.24 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 17 Jun 2025 | 6.00 (-10.85%) | Sell | 6.49 |
| JP Morgan | 09 May 2025 | 7.00 (4.01%) | Sell | 5.98 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ALTON GREGG H | - | - | 0 | 0 |
| DOUGLAS RICHARD | - | - | 0 | 0 |
| KING RACHEL K. | - | - | 0 | 0 |
| MCGLYNN MARGARET G | - | - | 0 | 0 |
| MOTT DAVID M | - | - | 0 | 0 |
| RODGERS RICHARD J | - | - | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| DOUGLAS RICHARD | Director | 12 Jun 2025 | Option execute | 10,420 | - | - |
| MOTT DAVID M | Director | 12 Jun 2025 | Option execute | 10,420 | - | - |
| RODGERS RICHARD J | Director | 12 Jun 2025 | Option execute | 10,420 | - | - |
| KING RACHEL K. | Director | 12 Jun 2025 | Option execute | 10,420 | - | - |
| ALTON GREGG H | Director | 12 Jun 2025 | Option execute | 10,420 | - | - |
| MCGLYNN MARGARET G | Director | 12 Jun 2025 | Option execute | 10,420 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |